NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19
NeuroRx, Inc., in partnership with RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” today announced that the U.S. Food and Drug Administration (FDA) awarded Fast Track designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19. RLF-100 is a synthetic form of human Vasoactive Intestinal Peptide (VIP) which reduces inflammation in the lungs and protects the alveolar type II cells that are believed to be an entry route for the SARS-CoV-2 to invade the lungs.
As part of NeuroRx's enrollment in the Fast Track program, the FDA has requested that NeuroRx submit a publicly-available expanded access policy, so that physicians may request RLF-100 for their patients who are being treated in hospitals not participating in the ongoing Phase 2/3 clinical trials.
“We at NeuroRx are enormously appreciative of the FDA's commitment to accelerating the development of any potential treatment for COVID-19. We hope to live up to the trust that has been placed in us by bringing a life-saving treatment to patients,” said Prof. Jonathan Javitt, MD, MPH, CEO and Chairman of NeuroRx.
“This milestone demonstrates the effectiveness of the FDA CoronaVirus Treatment Acceleration Program and the FDA's achievement in rising up to address the most severe public health crisis of our lifetime,” said former FDA Chief Counsel, Daniel Troy, a member of the Company's board of directors.
RLF-100 is being tested in Phase 2/3 clinical trials at major medical centers including the University of Miami, Houston Methodist Hospital, University of California-Irvine, the NYU Langone Medical Center, and the Rambam Healthcare Campus (Haifa, Israel). The multicenter clinical trial enrolls patients with Critical COVID-19 and respiratory failure in the hopes that RLF-100 can decrease mortality and improve blood oxygenation in this condition by rescuing alveolar type II cells from the SARS-CoV-2 virus.
Details of the study are posted on clinicaltrials.gov NCT04311697.
RLF-100 (Aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said's original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is primarily concentrated in the lung and is known to protect against a variety of lung injuries. VIP was awarded Orphan Drug Designation in 2001 by the U.S. FDA for treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. The European Medicines Agency awarded orphan drug designation in 2006 for the treatment of acute lung injury and in 2007 for the treatment of sarcoidosis.
About VIP in Lung Injury
Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the alveolar type II cell, that is critical to transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.
COVID-19-related death is primarily caused by Respiratory Failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type II cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Corona Viruses are shown to replicate in alveolar type II cells, but not in the more numerous type 1 cells. These same alveolar type II cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.
Injury to the alveolar type II cells is an increasingly plausible mechanism of COVID-19 disease progression. (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and are essential for oxygen exchange. Other than RLF-100, no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.
About RELIEF THERAPEUTICS Holding AG
The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF.
About NeuroRx, Inc.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX- 101 for the treatment of suicidal bipolar depression and is currently in Phase 3 trials.
Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Jonathan C. Javitt, M.D., MPH
Chief Executive Officer
Yves Sagot, Ph.D.
Relief Therapeutics Holding, SA
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enlighted Launches Game Changing Building IoT Sensor for Corporate Real Estate9.7.2020 12:00:00 CEST | Press release
Enlighted, the leading building IoT platform provider, now offers its award-winning technology in a new Surface Sensor designed for quick and easy deployments at scale across enterprise portfolios. Enlighted’s newest sensor makes activity-based workspaces, conference rooms and commercial buildings smarter, safer, more efficient and improves the occupant experience. The IoT technology enables intelligent desks that know when employees are using them, creates smart conference rooms that release themselves when a meeting is completed early and informs workplace planners on everything from physical distancing compliance to real estate utilization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005285/en/ The Enlighted USB-powered Surface Sensor (Photo: Business Wire) “More organizations than ever are looking to building IoT technology for data-driven decisions to help solve today’s and tomorrow’s challenges,” said Stefan S
ProteinQure Collaborates with AstraZeneca to Design Novel Peptide Therapeutics9.7.2020 10:00:00 CEST | Press release
ProteinQure, a leader in computational protein drug discovery, announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the creation of therapeutic libraries with the aim of accelerating the research and development of peptide therapeutics. Peptide therapeutics have unique properties that make them highly effective against some disease targets outside the scope of traditional small molecule and antibody modalities. However, due to the number of peptide variations, very few of these potential therapeutics have been studied. Integrating high-accuracy biophysical models and machine learning, it is possible to explore this vast therapeutic space and design peptide libraries with broad applicability in drug discovery. The collaboration will leverage ProteinQure's expertise in computational methods and structure-based drug design. AstraZeneca will conduct experimental validation, drawing on the company’s extensive expertise in biologi
KCOM extends high-speed connectivity with ADVA’s packet edge solution9.7.2020 09:00:00 CEST | Press release
ADVA (FSE: ADV) today announced that KCOM has deployed its packet edge technology to support the extended rollout of super-fast full fiber broadband. Using the compact ADVA FSP 150 demarcation and aggregation device, the UK-based communication and IT service provider is delivering its gigabit-speed Lightstream services to tens of thousands more business and residential customers in the Yorkshire and Lincolnshire area. The high-density MEF 3.0-certified technology enables KCOM to smoothly transition from 1Gbit/s to 10Gbit/s services in its access network. ADVA’s packet edge solution also ensures that the new infrastructure is ready for 5G mobile services and can easily scale to 200Gbit/s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005034/en/ ADVA is helping KCOM to build the UK’s first full-fiber city (Photo: Business Wire) “Our Lightstream service has already had a huge impact on businesses and in homes across this
RAM Active Investments Launches an AI-Driven Sustainable Fund Solution for the Climate Transition9.7.2020 09:00:00 CEST | Press release
RAM Active Investments SA ("RAM AI"), a systematic asset manager based in Geneva, is launching a fund with the objective to tackle the climate emergency and to provide investors an active strategy with strong ESG standards. RAM AI’s innovative ESG approach is the result of extensive research exploring alternative data thanks to the successful development of the RAM AI Machine Learning (ML) infrastructure. As the Climate Change emergency continues to grow RAM AI believes its role as an asset manager is to provide investors with a differentiated solution to low-carbon investing. Emmanuel Hauptmann who heads the Systematic Equity research shares: “The RAM ML team has made tremendous advances in building the strategy with the objective to provide a selection of best-in-class, low-carbon companies without compromising performance.” While many managers opt for a unidimensional approach to climate change within portfolios by reducing the weight of the worst polluters, RAM AI’s sustainable alp
Celebrity Stylist Tara Swennen and Glamhive Founder Stephanie Sprangers Once Again Bring Together Some of the Biggest Names from Around the World in Style, Fashion, Beauty and Women’s Empowerment for Groundbreaking Digital Event8.7.2020 22:20:00 CEST | Press release
Celebrity stylist Tara Swennen and Glamhive founder Stephanie Sprangers will once again bring together some of the biggest names from around the world in style, fashion, beauty and women’s empowerment for the Glamhive Digital Summer Bazaar—a groundbreaking digital event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200708005857/en/ Adir Abergel, Celebrity Hair Stylist (Photo: Glamhive) During Glamhive’s first digital event, Glamhive LIVE Style Summit, audience members were asked to engage with panels through live, real-time question and answer sessions. The conversations ranged from intimate questions about how to break down gender barriers when starting a business to how to find ways to break in into business through marketing. Due to that event’s overwhelming success, Swennen and Sprangers decided to raise the bar for their next global event. “The style, beauty, and designer communities are a close-knit one; many of us h
International WELL Building Institute Opens Enrollment for WELL Health-Safety Rating In Response to COVID-19 With Significant Early Adoption8.7.2020 19:18:00 CEST | Press release
The International WELL Building Institute (IWBI) announced that enrollment has opened today for the WELL Health-Safety Rating for Facility Operations and Management, with more than 100 organizations and real estate portfolios across the globe already enrolled. Organizations across a wide range of industries and geographic locations have responded swiftly to implement the program’s science-backed guidance as they seek to instill confidence and trust among their staff, stakeholders and the broader community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200708005768/en/ The WELL Health-Safety Rating is an evidence-based, third-party verified rating for all new and existing building and space types focused on operational policies, maintenance protocols, emergency plans and stakeholder engagement strategies to help organizations prepare their spaces for re-entry in a post COVID-19 environment. Adapted from features in the WELL